Lupin inks pact with South Korean firm to launch diabetes drug

Tags: Companies
Drug major Lupin has inked a marketing pact with South Korea's LG Life Sciences to launch its anti-diabetes drug in India.

As per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine, a novel insulin analogue, under the brand name BasugineTM.

"According to the agreement, Lupin would be responsible for marketing and sales of BasugineTM in India," Lupin Ltd said in a statement.

Insulin Glargine is indicated for the treatment of adult patients with type 1 diabetes mellitus or in type 2 diabetes mellitus.

Commenting on the development, Lupin Group President, India Region Formulations, Shakti Chakraborty said: "I believe that our entry into the insulin analogue market with launch of BasugineTM is a step in the right direction."

Lupin's foray in this segment will help the company further strengthen its diabetes portfolio enabling it to grow deeper into the segment and fuel growth in the years to come, he added.

According to IMS MAT data, the overall diabetes market size within the Indian pharmaceutical Market (IPM) stood at Rs 6,032 crore, growing at 18 per cent year-on-year.

The total insulin analogue market size is valued at Rs 585 crore with three year CAGR of 24 per cent while the total Glargine molecule market is estimated to be around Rs 218.5 crore.

Lupin's shares were trading 0.17 per cent down at Rs 1,175.45 apiece during afternoon trade on the BSE.


  • Peeved Akhilesh indicates family truce is a distant dream

    In the closed environs of a family-driven political party, it is unusual to witness open revolt from a young family member when the patriarch is still


Stay informed on our latest news!


Urs Schoettli

Just how useful are summits?

In the age of globalisation international summits play an increasingly ...

Zehra Naqvi

Of absolute truth & relative perception

Is there such a thing as absolute truth? Look around ...

Shona Adhikari

When art meets the artful

This week’s art news focuses on vastly different themes and ...